Rhodium complex [RhLI2]I: a novel anticancer agent inducing tumor inhibition and apoptosis
Abstract Numerous chemotherapeutic agents are currently employed in cancer treatment, but many are associated with significant side effects. This study aims to identify a novel anticancer drug that minimizes or eliminates these adverse effects. The anticancer activity of the Rhodium (III) complex ci...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer
2024-12-01
|
| Series: | Discover Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s12672-024-01632-7 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850133707165270016 |
|---|---|
| author | M. Matakabbir Hossain Kazi Soha Arifur Rahman Abdul Auwal Tasfik Ul Haque Pronoy K. M. Rashel M. Nurujjaman Habibur Rahman Tapashi G. Roy Jahan Ara Khanam Farhadul Islam |
| author_facet | M. Matakabbir Hossain Kazi Soha Arifur Rahman Abdul Auwal Tasfik Ul Haque Pronoy K. M. Rashel M. Nurujjaman Habibur Rahman Tapashi G. Roy Jahan Ara Khanam Farhadul Islam |
| author_sort | M. Matakabbir Hossain |
| collection | DOAJ |
| description | Abstract Numerous chemotherapeutic agents are currently employed in cancer treatment, but many are associated with significant side effects. This study aims to identify a novel anticancer drug that minimizes or eliminates these adverse effects. The anticancer activity of the Rhodium (III) complex cis-[RhLI2]I was evaluated through both in vivo and in vitro functional assays. Apoptosis in cancer cells post-treatment was assessed using microscopy and gene expression analysis. In cytotoxicity screening via the brine shrimp lethality bioassay, the compound exhibited an LC50 value of 25.90 µg/mL (P < 0.001). It also achieved an 88.96% inhibition of cell growth (P < 0.001), an 82.39% increase in lifespan (P < 0.001), and a significant reduction in tumor weight at a dosage of 200 µg/kg in Ehrlich ascites carcinoma (EAC)-bearing Swiss albino mice. Restoration of hematological parameters, such as RBC, WBC, and hemoglobin levels, was observed in treated tumor-bearing mice compared to untreated EAC-bearing mice. The compound inhibited the growth and proliferation of breast cancer (MCF7) cells in a dose-dependent manner, achieving a maximum inhibition of 88.9% at 200 µg/mL. Apoptotic induction in MCF7 cells occurred through the upregulation of p53, Bax, caspase-3, -8, and -9, alongside the downregulation of the anti-apoptotic protein Bcl-2. No long-term adverse effects on hematological or biochemical parameters or tissue levels were observed in the mice. Given these findings, this compound demonstrates significant cytotoxic effects and has the potential to serve as a promising chemotherapeutic agent, warranting further investigation at more advanced stages. |
| format | Article |
| id | doaj-art-b0ff6fe127594de4aaa38f1b1fd25d33 |
| institution | OA Journals |
| issn | 2730-6011 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Springer |
| record_format | Article |
| series | Discover Oncology |
| spelling | doaj-art-b0ff6fe127594de4aaa38f1b1fd25d332025-08-20T02:31:54ZengSpringerDiscover Oncology2730-60112024-12-0115111710.1007/s12672-024-01632-7Rhodium complex [RhLI2]I: a novel anticancer agent inducing tumor inhibition and apoptosisM. Matakabbir Hossain0Kazi Soha1Arifur Rahman2Abdul Auwal3Tasfik Ul Haque Pronoy4K. M. Rashel5M. Nurujjaman6Habibur Rahman7Tapashi G. Roy8Jahan Ara Khanam9Farhadul Islam10Department of Biochemistry and Molecular Biology, University of RajshahiDepartment of Biochemistry and Molecular Biology, University of RajshahiDepartment of Biochemistry and Molecular Biology, University of RajshahiDepartment of Biochemistry and Molecular Biology, University of RajshahiDepartment of Biochemistry and Molecular Biology, University of RajshahiDepartment of Biochemistry and Molecular Biology, University of RajshahiDepartment of Biochemistry and Molecular Biology, University of RajshahiDepartment of Chemistry, University of RajshahiDepartment of Chemistry, Faculty of Science, University of ChittagongDepartment of Biochemistry and Molecular Biology, University of RajshahiDepartment of Biochemistry and Molecular Biology, University of RajshahiAbstract Numerous chemotherapeutic agents are currently employed in cancer treatment, but many are associated with significant side effects. This study aims to identify a novel anticancer drug that minimizes or eliminates these adverse effects. The anticancer activity of the Rhodium (III) complex cis-[RhLI2]I was evaluated through both in vivo and in vitro functional assays. Apoptosis in cancer cells post-treatment was assessed using microscopy and gene expression analysis. In cytotoxicity screening via the brine shrimp lethality bioassay, the compound exhibited an LC50 value of 25.90 µg/mL (P < 0.001). It also achieved an 88.96% inhibition of cell growth (P < 0.001), an 82.39% increase in lifespan (P < 0.001), and a significant reduction in tumor weight at a dosage of 200 µg/kg in Ehrlich ascites carcinoma (EAC)-bearing Swiss albino mice. Restoration of hematological parameters, such as RBC, WBC, and hemoglobin levels, was observed in treated tumor-bearing mice compared to untreated EAC-bearing mice. The compound inhibited the growth and proliferation of breast cancer (MCF7) cells in a dose-dependent manner, achieving a maximum inhibition of 88.9% at 200 µg/mL. Apoptotic induction in MCF7 cells occurred through the upregulation of p53, Bax, caspase-3, -8, and -9, alongside the downregulation of the anti-apoptotic protein Bcl-2. No long-term adverse effects on hematological or biochemical parameters or tissue levels were observed in the mice. Given these findings, this compound demonstrates significant cytotoxic effects and has the potential to serve as a promising chemotherapeutic agent, warranting further investigation at more advanced stages.https://doi.org/10.1007/s12672-024-01632-7Antineoplastic activityChemotherapyCytotoxic activityApoptosisEAC cells |
| spellingShingle | M. Matakabbir Hossain Kazi Soha Arifur Rahman Abdul Auwal Tasfik Ul Haque Pronoy K. M. Rashel M. Nurujjaman Habibur Rahman Tapashi G. Roy Jahan Ara Khanam Farhadul Islam Rhodium complex [RhLI2]I: a novel anticancer agent inducing tumor inhibition and apoptosis Discover Oncology Antineoplastic activity Chemotherapy Cytotoxic activity Apoptosis EAC cells |
| title | Rhodium complex [RhLI2]I: a novel anticancer agent inducing tumor inhibition and apoptosis |
| title_full | Rhodium complex [RhLI2]I: a novel anticancer agent inducing tumor inhibition and apoptosis |
| title_fullStr | Rhodium complex [RhLI2]I: a novel anticancer agent inducing tumor inhibition and apoptosis |
| title_full_unstemmed | Rhodium complex [RhLI2]I: a novel anticancer agent inducing tumor inhibition and apoptosis |
| title_short | Rhodium complex [RhLI2]I: a novel anticancer agent inducing tumor inhibition and apoptosis |
| title_sort | rhodium complex rhli2 i a novel anticancer agent inducing tumor inhibition and apoptosis |
| topic | Antineoplastic activity Chemotherapy Cytotoxic activity Apoptosis EAC cells |
| url | https://doi.org/10.1007/s12672-024-01632-7 |
| work_keys_str_mv | AT mmatakabbirhossain rhodiumcomplexrhli2ianovelanticanceragentinducingtumorinhibitionandapoptosis AT kazisoha rhodiumcomplexrhli2ianovelanticanceragentinducingtumorinhibitionandapoptosis AT arifurrahman rhodiumcomplexrhli2ianovelanticanceragentinducingtumorinhibitionandapoptosis AT abdulauwal rhodiumcomplexrhli2ianovelanticanceragentinducingtumorinhibitionandapoptosis AT tasfikulhaquepronoy rhodiumcomplexrhli2ianovelanticanceragentinducingtumorinhibitionandapoptosis AT kmrashel rhodiumcomplexrhli2ianovelanticanceragentinducingtumorinhibitionandapoptosis AT mnurujjaman rhodiumcomplexrhli2ianovelanticanceragentinducingtumorinhibitionandapoptosis AT habiburrahman rhodiumcomplexrhli2ianovelanticanceragentinducingtumorinhibitionandapoptosis AT tapashigroy rhodiumcomplexrhli2ianovelanticanceragentinducingtumorinhibitionandapoptosis AT jahanarakhanam rhodiumcomplexrhli2ianovelanticanceragentinducingtumorinhibitionandapoptosis AT farhadulislam rhodiumcomplexrhli2ianovelanticanceragentinducingtumorinhibitionandapoptosis |